Trial Profile
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Triciribine (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; Ductal carcinoma; Early breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TCN-PM
- Sponsors Prescient Therapeutics
- 17 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 06 Apr 2020 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 24 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 Apr 2020.